Cargando…

Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease

Tauvid has been approved by the U.S. Food and Drug Administration (FDA) in 2020 for positron emission tomography (PET) imaging of adult patients with cognitive impairments undergoing evaluation for Alzheimer’s disease (AD) based on tau pathology. Abnormal aggregation of tau proteins is one of the ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jie, Caitlin V. M. L., Treyer, Valerie, Schibli, Roger, Mu, Linjing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911942/ https://www.ncbi.nlm.nih.gov/pubmed/33573211 http://dx.doi.org/10.3390/ph14020110

Ejemplares similares

Radiation dosimetry of (18)F-AzaFol: A first in-human use of a folate receptor PET tracer
por: Gnesin, Silvano, et al.
Publicado: (2020)

Discriminatory ability of next-generation tau PET tracers for Alzheimer’s disease
por: Yap, Steven Y, et al.
Publicado: (2021)

Radiation dosimetry of [(18)F]-PSS232—a PET radioligand for imaging mGlu5 receptors in humans
por: Sah, Bert-Ram, et al.
Publicado: (2019)

The Sensitivity of Tau Tracers for the Discrimination of Alzheimer’s Disease Patients and Healthy Controls by PET
por: Mohammadi, Zohreh, et al.
Publicado: (2023)

Clinical evaluation of [(18)F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer’s disease
por: Schmidt, Mark E., et al.
Publicado: (2020)

Discovery and preclinical characterization of [(18)F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer’s disease and other tauopathies
por: Kroth, Heiko, et al.
Publicado: (2019)

The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer
por: Li, Mei, et al.
Publicado: (2022)

Reduced uptake of [11C]‐ABP688, a PET tracer for metabolic glutamate receptor 5 in hippocampus and amygdala in Alzheimer’s dementia
por: Treyer, Valerie, et al.
Publicado: (2020)

First vaccine approval under the FDA Animal Rule
por: Beasley, David W C, et al.
Publicado: (2016)

Immunotherapy for Breast Cancer: First FDA Approved Regimen
por: Soare, Georgiana R., et al.
Publicado: (2019)

[(68)Ga]Ga-DOTA-TOC: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging
por: Hennrich, Ute, et al.
Publicado: (2020)

Guidelines for pharmacotherapy in Alzheimer’s disease – A primer on FDA-approved drugs
por: Varadharajan, Ashvin, et al.
Publicado: (2023)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

PET Imaging of Tau Pathology in Alzheimer’s Disease and Tauopathies
por: James, Olga G., et al.
Publicado: (2015)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Bedaquiline: First FDA-approved tuberculosis drug in 40 years
por: Mahajan, Rajiv
Publicado: (2013)

Staging tau pathology with tau PET in Alzheimer’s disease: a longitudinal study
por: Chen, Shi-Dong, et al.
Publicado: (2021)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

Physiologically Based Pharmacokinetic Modelling with Dynamic PET Data to Study the In Vivo Effects of Transporter Inhibition on Hepatobiliary Clearance in Mice
por: Taddio, Marco F., et al.
Publicado: (2018)

Characterization of MK6240, a tau PET tracer, in autopsy brain tissue from Alzheimer’s disease cases
por: Malarte, Mona-Lisa, et al.
Publicado: (2020)

Cryptic Sites in Tau Fibrils Explain the Preferential Binding of the AV-1451 PET Tracer toward Alzheimer’s Tauopathy
por: Murugan, N. Arul, et al.
Publicado: (2021)

[(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2021)

The development and validation of tau PET tracers: current status and future directions
por: Okamura, Nobuyuki, et al.
Publicado: (2018)

Dissecting the Binding Profile of PET Tracers to Corticobasal Degeneration Tau Fibrils
por: Zhou, Yang, et al.
Publicado: (2021)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?
por: Sirohi, Devika, et al.
Publicado: (2017)

Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs
por: Nunes, Débora, et al.
Publicado: (2022)

Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
por: Hennrich, Ute, et al.
Publicado: (2019)

Remdesivir: the first FDA-approved anti-COVID-19 Treatment for Young Children
por: Chera, Alexandra, et al.
Publicado: (2022)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA-approved medications that impair human spermatogenesis
por: Ding, Jiayi, et al.
Publicado: (2016)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021)

FDA-Approved Oximes and Their Significance in Medicinal Chemistry
por: Dhuguru, Jyothi, et al.
Publicado: (2022)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022)

FDA approved vaccines for monkeypox: Current eminence
por: Chopra, Hitesh, et al.
Publicado: (2022)

Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains
por: Lemoine, Laetitia, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2kk45qo1mlutuuqaa7tpev6u7m